Sandoz, a Novartis division, is the pioneer and global leader in biosimilars. We invest in research and development to improve the lives of patients and liberate healthcare resources through increased access to high-quality, affordable biologics.
Biosimilars have contributed significantly to increasing patient access across Europe and beyond, both by freeing up funds for healthcare systems through much-needed competition and by driving increases in overall biologic usage.
Sandoz was the first pharmaceutical company to receive approval of a biosimilar in Europe, Japan and the United States1-3.
Our biosimilars have been used in clinical practice for over 10 years, are available in over 86 countries and have over 340 million patient-days of experience4-6.
Binocrit® (epoetin alfa)
Zarzio® / Zarxio® (filgrastim)
Supportive cancer care A human Granulocyte-Colony Stimulating Factor (G-CSF) used in neutropenia after chemotherapy
In addition to our marketed biosimilars, we also have a leading biosimilar pipeline with several molecules in various stages of development.
Sandoz has over 20 years of experience in biosimilar development1. This has equipped us with extensive knowledge and world-class expertise in the development, manufacture and delivery of biosimilar medicines to the healthcare community and patients.
We have a unique heritage in pharmaceutical biotechnology that dates back to the 1940s, with the development of penicillin7. In 1980, Sandoz produced one of the first recombinant proteins, an interferon alfa8.
After initiating the world’s first biosimilar development program in 1996, we went on to receive the world’s first approval of a biosimilar – Omnitrope® (somatropin) – in Europe over a decade ago1. Then, in 2015, Zarxio® (filgrastim) was the first biosimilar to be granted marketing authorization in the US3.
We have an unparalleled heritage in advancing biologic care – longer than any other company.